HER-2 positivity and correlations with other histopathologic features in breast cancer patients - Hospital based study

Journal of the Pakistan Medical Association

Volumn 56, Issue 2, 2006, Pages 65-68

  Al Ahwal, Mahmoud S ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CLINICAL FEATURE; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; REVIEW; SAUDI ARABIA; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; FEMALE; GENES, ERBB-2; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SAUDI ARABIA;

EID: 33646249631     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Cancer Incidence Report Saudi Arabia 1999-2000. National Cancer Registry, Ministry of Health, Kingdom of Saudi Arabia, 2004.
2. Klijn JGM, Foekens JA. Prognostic factors in breast cancer. In: A Goldhirsch, ed. Endocrine treatment of breast cancer IV. Monograph Series of the European School of Oncology 1990;17-25.
3. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined Hormone Agents Trialists Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone (LHRH) agonist versus LHRH, agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343-53.
4. Benz C, Tripathy D. ErbB2 overexpression in breast cancer: biology and clinical translation. J Womens Cancer 2000;2:33-40.
5. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, et al. Randomized adjuvant trial of tamoxifen and goserlin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group 5. J Clin Oncol 2002;20:4621-7.
6. Al-Kuraya K, Schrami P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer. Cancer Research 2004;64:8534-40.
7. Eppenberger-Castori S, Moore DM, Thor AD, Edgerton SM, Kueng W, Eppenberger U, et al. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 2002;34:1318-30.
8. Krtolica A, Parrinello S, Lockett S, Desprez P, Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorgenesis: a link between cancer and aging. Proc Natl Acad Sci USA 2001;12072-7.
9. Eppenberger-Castori S, Kueng W, Benz CC, Paris K. Caduff R, Bannwart F, et al. Prognostic and predictive significance of ErbB2 breast tumor levels measured by enzyme immunoassay (EIA). J Clin Oncol 2001;19:645-56.
10. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, et al. Quantitative association between HER2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.